OpenResearchAlpha

Frontiers in Immunology · 20 Nov 2026

Baseline and early on-treatment immune profiling in patients with pleural mesothelioma on dual immune checkpoint inhibition

Solfrid Thunold, Mehrdad Rakaee, Krinio Giannikou, Astrid Marie Dalsgaard, Elisabeth Müller, Saima Farooqi, Åsa Kristina Öjlert, Carin Meltzer, Lars Tore Gyland Mikalsen, Eivor Hernes, Eirik Malinen, Åslaug Helland, Vilde Drageset Haakensenh-index 12

0
Citations
no database records one yet
0
Citations in 2026
so far
12
Leading author's h-index
Vilde Drageset Haakensen, in QAI's scholar index
65
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Background Pleural mesothelioma (PM) has limited treatment options. Only a minority of patients achieve durable clinical benefit from dual immune checkpoint inhibition (ICI), and biomarkers of response are lacking. In this study, we used RNA sequencing to characterise the tumour microenvironment (TME) at baseline and early on treatment and explored its associations with response to dual ICI. Methods Patients with PM treated in second-line with nivolumab/ipilimumab ± UV1 telomerase peptide vaccine underwent tumour biopsies at baseline and week 5. Bulk RNA sequencing was performed, followed by differential gene expression, Hallmark gene set enrichment analyses, xCell cell-type deconvolution, and evaluation of a four-gene inflammatory signature ( CD8A, STAT1, LAG3, CD274 ), each explored in relation to objective response and durable disease control (objective response or stable disease lasting ≥ 24 weeks). Survival analyses were performed to evaluate associations with the ImmuneScore and the four-gene inflammatory signature. Results Bulk RNA sequencing was successfully performed in 31 baseline and 23 week 5 biopsies (17 paired). At baseline, interferon/inflammatory Hallmark gene sets were enriched in objective responders. For durable disease control, inflammatory/interferon gene sets were positively enriched, and cell-cycle/proliferation gene sets negatively enriched; only the latter remained after excluding objective responders. Unsupervised hierarchical clustering identified an immune-enriched/stromal-low and a stromal-enriched/immune-poor TME cluster at baseline, and a similar, less distinct pattern at week 5. Four of five objective responders at baseline, and all three objective responders at week 5, were in the immune‐enriched cluster. Objective responders showed higher xCell-derived ImmuneScore and four-gene inflammatory signature scores at both time points, and higher CD8 + T‐cell scores and lower StromaScore at baseline only. Neither baseline ImmuneScore nor the four-gene signature was associated with overall survival. Longitudinal analyses of 17 paired biopsies demonstrated an increase in ImmuneScore in most patients, while changes in StromaScore were heterogeneous. Conclusion An immune‐enriched/stromal‐low TME pattern, high four‐gene inflammatory signature scores and enrichment of inflammatory/interferon gene sets were associated with objective response to dual ICI in PM. These exploratory findings require validation in larger cohorts. Clinical trial registration https://clinicaltrials.gov/study/NCT04300244 , identifier NCT04300244.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Vilde Drageset Haakensen has the highest h-index among the authors (12).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (13)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (65)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 45 more references

A free account opens the rest of the citing papers and references on every paper’s page.

Baseline and early on-treatment immune profiling in patients with pleural mesothelioma on dual immune checkpoint inhibition - QAI OpenResearch